Developing new cancer treatment strategies for diverse populations
Official title: Pilot Projects and Trans-Network Activities
Funded at University of California at Davis · NIH-10896254 · Data updated 2026-11-12
This study is looking at new ways to treat gastric and lung cancers by using cancer cells from patients and testing them in mice, especially focusing on helping Latino and Asian American communities, and patients can join clinical trials to see how well new drug combinations work.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $138,846 |
| NIH project number | 5U54CA283766-02 |
| Project ID | NIH-10896254 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include Latino, African American, and Asian American patients diagnosed with gastric or lung cancer.
✕Less likely to help
Patients with cancers not focused on in this research, or those outside the specified racial and ethnic groups, may not receive benefit from this research.
What this research studies
This research focuses on creating and testing new cancer treatment strategies using patient-derived xenografts (PDX), which involve implanting cancer cells from patients into mice to study their behavior and response to drugs. The project specifically targets gastric and lung cancers, which disproportionately affect Latino and Asian American populations. By involving diverse racial and ethnic groups, the research aims to address cancer health disparities and improve treatment outcomes. Patients may have the opportunity to participate in clinical trials that evaluate the effectiveness of new drug combinations.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments tailored to diverse populations, ultimately improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in using patient-derived xenografts to develop targeted cancer therapies, indicating a potential for success in this approach.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Chen, Moon Shao-Chuang — University of California at Davis
- Study coordinator: Chen, Moon Shao-Chuang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.